Cyltezo will be commercially available in the U.S. on July 1, 2023.

Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports.

Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimumab) and was initially approved in 2017. Cyltezo will be commercially available in the U.S. on July 1, 2023.

"Optum Rx's decision to add Cyltezo to its formulary could benefit millions of Americans, improving access to a crucial medicine that has been a safe and effective treatment for many inflammatory conditions for the last two decades," says Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim, in a news release. "We are proud to bring our many decades of experience in complex biologics to the biosimilar space, enabling physicians and patients to feel confident in the science, Interchangeability and manufacturing of Cyltezo."